Adagio Medical Holdings Inc (ADGM) News & EventsADGMAdagio Medical Holdings Inc

Adagio Medical Initiates Strategic Alternatives Review and Workforce Reduction

Adagio Medical announced that its Board of Directors has completed a comprehensive review of the Company's business, programs, resources and capabilities and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. In connection with this decision, the Company is implementing a reduction in workforce to align its cost structure with its prioritized programs. Adagio will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. There can be no assurance that its exploration will result in Adagio pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. Adagio has not set a timetable for completion of this evaluation process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary. As of June 30, 2026, the Company had a preliminary unaudited amount of approximately $7.7M in cash, cash equivalents and investments in marketable securities.

Adagio Medical Enrolls First Patient in vCLAS Ultra Study

Adagio Medical Holdings announced highlights from the first patient enrolled in the Company's study evaluating its next-generation vCLAS Ultra Ultra-Low Temperature Ablation, ULTA, Ventricular Ablation System. The study is designed to support a Premarket Approval, PMA, supplement to the Company's PMA for its first generation vCLAS system, which is presently under review by the to the U.S. Food and Drug Administration. The supplemental study is being conducted under the Company's FDA-approved Investigational Device Exemption designed to evaluate the safety and effectiveness of the vCLAS Ultra System for the treatment of Sustained Monomorphic Ventricular Tachycardia.

Adagio Medical CEO Highlights Significant Progress in Technology

"This quarter marked an inflection point for Adagio as our team continues to execute and deliver on our critical milestones. The enthusiastic physician reception of our FULCRUM-VT late-breaking data at HRS reinforced what we have long believed about the potential for this technology, and the successful treatment of the first patient with vCLAS Ultra - a particularly complex case - was a powerful proof point for our next-generation system," said Todd Usen, Chief Executive Officer of Adagio Medical. "We believe our progress - combined with the breadth of our clinical evidence for both ischemic and non-ischemic patients - positions our fully-endocardial ULTA platform as a uniquely differentiated solution capable of treating the entire spectrum of cases in an addressable market that has long needed a purpose-built solution. We remain focused on executing against the milestones ahead as we work to bring our proprietary technology to the many patients who suffer from VT."